Hepatitis C Diagnosis and Treatment Market Research Report - Global Forecast till 2025

Report / Search Code: MRFR/MED/1040-HCR       Publish Date: January, 2020

Request Sample

| Price       | 1-user PDF : $ 4450.0 | Enterprise PDF : $ 6250.0 |

Description:

Global Hepatitis C Diagnosis and Treatment Market Research Report: By Diagnosis (Liver Function Tests, Liver Biopsy, Blood Tests and others), Treatment (Antiviral Medications, Immuno-Modulators, Liver Transplantation and others), End User (Hospitals & Clinics, Diagnostic Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025

Market Scenario

Hepatitis C Diagnosis and Treatment Market is expected to exhibit significant growth over the forecast period. The market is projected to register a 3.82% CAGR over the forecast period.

Hepatitis C is a liver infection that is caused due to the hepatitis C virus. The hepatitis C virus may cause both acute as well as chronic hepatitis. It is a bloodborne virus and is commonly infected through small quantities of blood.

Factors such as the high prevalence of hepatitis C and increasing awareness regarding the disease are expected to drive the market growth. According to an article published by the World Health Organization (WHO) in July 2019, an estimated 71 million people suffer from chronic hepatitis C virus infection, globally.

However, stringent government regulations and alternate treatment options, such as herbal treatment offered at comparatively lower prices are expected to hamper the market growth.

Segmentation

The Global Hepatitis C Diagnosis and Treatment Market has been segmented into diagnosis, treatment, end-user, and region.

Based on diagnosis, the global hepatitis C diagnosis and treatment market has been divided into liver function tests, liver biopsy, blood tests, and others.

The global hepatitis C diagnosis and treatment market, by treatment, has been segmented into antiviral medications, immune-modulators, liver transplantation, and others.

The global hepatitis C diagnosis and treatment market, by end-user, has been segmented into hospitals & clinics, diagnostic centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The hepatitis C diagnosis and treatment market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European hepatitis C diagnosis and treatment market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe.

The hepatitis C diagnosis and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The Middle East & Africa hepatitis C diagnosis and treatment market has been segmented into the Middle East and Africa.
Key Players

- Hoffmann-La Roche Ltd (Switzerland), Vertex Pharmaceuticals Incorporated (US), Gilead Sciences, Inc. (US), AbbVie Inc. (US), GlaxoSmithKline PLC (UK), Novartis Pharmaceuticals Corporation (Switzerland), Bristol-Myers Squibb Company (US), Abbott (US), Beckman Coulter, Inc. (US), Siemens Medical Solutions USA, Inc. (Germany), MedMira Inc. (Canada), DiaSorin SpA (Italy), Qiagen (Germany), bioMérieux SA (France), Hologic, Inc. (US), and Bio-Rad Laboratories, Inc. (US) are some of the Key Players operating in the Global Hepatitis C Diagnosis and Treatment Market.

Regional Market Summary

Global Hepatitis C Diagnosis and Treatment Market Share (%), by Region, 2018

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports

Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the hepatitis C diagnosis and treatment market owing to the increasing patient population suffering from hepatitis C and presence of major players, such as Vertex Pharmaceuticals Incorporated, AbbVie Inc., Bristol-Myers Squibb Company, Abbott, Beckman Coulter, Inc., Hologic, Inc., and Bio-Rad Laboratories, Inc. in the region. According to a report published by the Centers for Disease Control and Prevention in July 2019, approximately 2.4 million people in the US are suffering from hepatitis C.

Europe is expected to hold the second-largest position in the global hepatitis C diagnosis and treatment market owing to the growing awareness regarding hepatitis C and the rising patient population suffering from the disease. According to the WHO, as of 2018, 14 million people in Europe suffered from hepatitis C.

Asia-Pacific is expected to be the fastest-growing regional market owing to the high patient population suffering from hepatitis C and rising number of initiatives taken by governments as well as private institutes to create awareness regarding hepatitis C. For instance, In June 2015, Abbott launched “LiverHealth”, an initiative to provide easy diagnosis of liver health and to raise awareness regarding hepatitis C in India.

The hepatitis C diagnosis and treatment market in the Middle East & Africa is expected to grow slowly, owing to the rising patient population suffering from hepatitis C. According to the WHO, 10 million people in Africa suffer from chronic viral hepatitis C.

Global Hepatitis C Diagnosis and Treatment Market, by Diagnosis

- Liver Function Tests
- Liver Biopsy
- Blood Tests
Global Hepatitis C Diagnosis and Treatment Market, by Treatment
- Antiviral Medications
- Immuno-Modulators
- Liver Transplantation
- Others

Global Hepatitis C Diagnosis and Treatment Market, by End User
- Hospitals and Clinics
- Diagnostic Centers
- Others

Global Hepatitis C Diagnosis and Treatment Market, by Region
- Americas
  - North America
    - US
    - Canada
  - Latin America
- Europe
  - Western Europe
    - Germany
    - France
    - Italy
    - Spain
    - UK
    - Rest of Western Europe
  - Eastern Europe
- Asia-Pacific
  - Japan
  - China
  - India
  - Australia
  - South Korea
  - Rest of Asia-Pacific
- Middle East & Africa
  - Middle East
  - Africa

Intended Audience
- Biotechnology and Pharmaceutical Companies
- Research Institutes
- Medical Device Companies
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Academic Institutes
- Government Organizations
2.2.2.    Assumptions
2.2.3.    Limitations

3.    RESEARCH METHODOLOGY
3.1.    Overview
3.2.    Primary Research
3.3.    Secondary Research
3.4.    Market Size Estimation
4.    MARKET DYNAMICS
4.1.    Overview
4.2.    Drivers
4.3.    Restraints
4.4.    Opportunities
5.    MARKET FACTOR ANALYSIS
5.1.    Porter’s Five Forces Analysis
5.1.1.    Bargaining Power of Suppliers
5.1.2.    Bargaining Power of Buyers
5.1.3.    Threat of New Entrants
5.1.4.    Threat of Substitutes
5.1.5.    Intensity of Rivalry
5.2.    Value Chain Analysis

6.    GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS
6.1.    Overview
6.2.    Liver Function Tests
   Market Estimates & Forecast, by Region, 2019–2025
6.3.    Liver Biopsy
   Market Estimates & Forecast, by Region, 2019–2025
6.4.    Blood Tests
   Market Estimates & Forecast, by Region, 2019–2025
6.5.    Others
   Market Estimates & Forecast, by Region, 2019–2025

7.    GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT
7.1.    Overview
7.2.    Antiviral Medications
   Market Estimates & Forecast, by Region, 2019–2025

7.3. Immuno-Modulators
Market Estimates & Forecast, by Region, 2019–2025

7.4. Liver Transplantation
Market Estimates & Forecast, by Region, 2019–2025

7.5. Others
Market Estimates & Forecast, by Region, 2019–2025

8. GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER
8.1. Overview
8.2. Hospitals and Clinics
Market Estimates & Forecast, by Region, 2019–2025
8.3. Diagnostic Centers
Market Estimates & Forecast, by Region, 2019–2025
8.4. Others
Market Estimates & Forecast, by Region, 2019–2025

9. GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa

10. COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Hepatitis C Diagnosis and Treatment Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of the Number of Developments in the Global Hepatitis C Diagnosis and Treatment Market
10.7. Key Developments and Growth Strategies
10.7.1. Product Launch/Service Deployment
10.7.2. Mergers and Acquisitions
10.7.3. Joint Ventures
10.8.1. Sales & Operating Income 2018
10.8.2. Major Players R&D Expenditure 2018
10.9. Major Players Capital Market Ratio

11. COMPANY PROFILES
11.1. F. Hoffmann-La Roche Ltd
11.1.1. Company Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Vertex Pharmaceuticals Incorporated
11.2.1. Company Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies

11.3. Gilead Sciences, Inc.
11.3.1. Company Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies

11.4. AbbVie Inc.
11.4.1. Company Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies

11.5. GlaxoSmithKline plc
11.5.1. Company Overview
11.5.2. Product Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies

11.6. Novartis Pharmaceuticals Corporation
11.6.1. Company Overview
11.6.2. Product Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies

11.7. Bristol-Myers Squibb Company
11.7.1. Company Overview
11.7.2. Product Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies

11.8.1. Company Overview
11.13.5. SWOT Analysis
11.13.6. Key Strategies
11.14. bioMérieux SA
11.14.1. Company Overview
11.14.2. Product Overview
11.14.3. Financial Overview
11.14.4. Key Developments
11.14.5. SWOT Analysis
11.14.6. Key Strategies
11.15. Hologic, Inc.
11.15.1. Company Overview
11.15.2. Product Overview
11.15.3. Financial Overview
11.15.4. Key Developments
11.15.5. SWOT Analysis
11.15.6. Key Strategies
11.16. Bio-Rad Laboratories, Inc.
11.16.1. Company Overview
11.16.2. Product Overview
11.16.3. Financial Overview
11.16.4. Key Developments
11.16.5. SWOT Analysis
11.16.6. Key Strategies
11.17. Others

12. APPENDIX
12.1. References
12.2. Related Reports

LIST OF TABLES

TABLE 1  GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SYNOPSIS, 2019–2025

TABLE 2  GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET ESTIMATES & FORECAST, 2019–2025 (USD MILLION)

TABLE 3  GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2019–2025 (USD MILLION)

TABLE 4  GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 5  GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 6  GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY REGION, 2019–2025 (USD MILLION)

TABLE 7  NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2019–
2025 (USD MILLION)

TABLE 8  NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 9  NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 10  US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2019–2025 (USD MILLION)

TABLE 11  US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 12  US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 13  CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2019–2025 (USD MILLION)

TABLE 14  CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 15  CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 16  LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2019–2025 (USD MILLION)

TABLE 17  LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 18  LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 19  EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2019–2025 (USD MILLION)

TABLE 20  EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 21  EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 22  WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2019–2025 (USD MILLION)

TABLE 23  WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 24  WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 25  EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2019–2025 (USD MILLION)

TABLE 26  EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 27  EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 28  ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2019–2025 (USD MILLION)

TABLE 29  ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)

TABLE 30  ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 31  MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2019–2025 (USD MILLION)

TABLE 32  MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2019–2025 (USD MILLION)
TABLE 33    MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2019–2025 (USD MILLION)

LIST OF FIGURES

FIGURE 1    RESEARCH PROCESS

FIGURE 2    MARKET STRUCTURE FOR THE GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET

FIGURE 3    MARKET DYNAMICS FOR THE GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET

FIGURE 4    GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY DIAGNOSIS, 2018 (%)

FIGURE 5    GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY TREATMENT TYPE, 2018 (%)

FIGURE 6    GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY END USER, 2018 (%)

FIGURE 7    GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY REGION, 2018 (%)

FIGURE 7    AMERICAS: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2018 (%)

FIGURE 8    NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 9    EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY REGION, 2018 (%)

FIGURE 10    WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 11    ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 12    MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 13    GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2018 (%)

FIGURE 14    F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS

FIGURE 15    F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 16    F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 17    VERTEX PHARMACEUTICALS INCORPORATED: KEY FINANCIALS

FIGURE 18    VERTEX PHARMACEUTICALS INCORPORATED: SEGMENTAL REVENUE

FIGURE 19    VERTEX PHARMACEUTICALS INCORPORATED: REGIONAL REVENUE

FIGURE 20    GILEAD SCIENCES, INC.: KEY FINANCIALS

FIGURE 21    GILEAD SCIENCES, INC.: SEGMENTAL REVENUE

FIGURE 22    GILEAD SCIENCES, INC.: REGIONAL REVENUE

FIGURE 23    ABBVIE INC.: KEY FINANCIALS

FIGURE 24    ABBVIE INC.: SEGMENTAL REVENUE

FIGURE 25    ABBVIE INC.: REGIONAL REVENUE

FIGURE 26    GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 27    GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 28    GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 29    NOVARTIS PHARMACEUTICALS CORPORATION: KEY FINANCIALS

FIGURE 30    NOVARTIS PHARMACEUTICALS CORPORATION: SEGMENTAL REVENUE